Join our daily newsletter At The Bell to receive exclusive market insights
- ResApp Health’s (RAP) smartphone application, ResAppDx, goes live on Indonesian online telehealth platform Alodokter
- ResAppDx is a smartphone-based acute respiratory disease diagnostic test, for use in telehealth, emergency department and primary care settings
- The Alodokter platform connects more than 50,000 doctors and 1500 hospitals and clinics with millions of Indonesian patients
- It also provides a wide array of services around telemedicine such as offline doctor booking, insurance services, e-pharmacy and digital healthcare content
- Shares have been up 5 per cent trading at 6.3 cents
ResApp Health’s (RAP) smartphone application, ResAppDx, has gone live on Indonesian telehealth platform Alodokter.
ResAppDx is a smartphone-based acute respiratory disease diagnostic test, for use in telehealth, emergency department and primary care settings.
ResApp’s machine learning algorithms use sound to diagnose and measure the severity of respiratory conditions without the need for additional accessories or hardware.
The Alodokter platform connects more than 50,000 doctors and 1500 hospitals and clinics with millions of Indonesian patients. It also provides a wide array of services around telemedicine such as offline doctor booking, insurance services, e-pharmacy and digital healthcare content.
ResApp CEO and Managing Director Tony Keating said the technology will provide doctors on the Alodokter platform an accurate way to assess patients who present with respiratory symptoms.
“We look forward to continuing the partnership as we scale into the opportunity to help improve the healthcare of the millions of Indonesians who rely on Alodokter for their healthcare,” said Dr Keating.
Shares were up 5 per cent, trading at 6.3 cents at 10.21am AEDT.
